Cancer immunotherapy via combining oncolytic virotherapy with chemotherapy: recent advances
Hardev Pandha(University of Surrey), Kevin J. Harrington(Royal Marsden NHS Foundation Trust)
Cited by 75
Related Papers
Phase I Trial of an ICAM-1-Targeted Immunotherapeutic-Coxsackievirus A21 (CVA21) as an Oncolytic Agent Against Non Muscle-Invasive Bladder Cancer
|Clinical Cancer Research|2019|120
Reovirus exerts potent oncolytic effects in head and neck cancer cell lines that are independent of signalling in the EGFR pathway
|BMC Cancer|2012|62
Delayed DNA double-strand break repair following platin-based chemotherapy predicts treatment response in head and neck squamous cell carcinoma
|British Journal of Cancer|2016|18
Xevinapant plus Chemoradiotherapy Negatively Sculpts the Tumor-Immune Microenvironment in Head and Neck Cancer
|Cancer Research Communications|2025|1